Want to see ANVS full AI Analyst Report?
Top Page
Annovis Bio
(NYSE:ANVS)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.00
▼(-43.82% Downside)
Action:Reiterated
Date:09/11/26
The score is primarily weighed down by weak financial performance (no revenue, large losses, and accelerating cash burn increasing funding risk) and a bearish technical setup (price below key moving averages with negative MACD). Corporate events provide a modest offset via a major clinical trial enrollment milestone, while valuation is difficult to assess meaningfully due to negative earnings and no dividend data.
Positive Factors
Debt-Free Balance Sheet
The absence of reported debt reduces refinancing and interest-rate risk while preserving financial flexibility relative to a leveraged clinical-stage peer. Although the company remains loss-making, avoiding debt service gives management more discretion over capital allocation as clinical development continues.
Negative Factors
No Commercial Revenue
A persistent absence of revenue means Annovis has not demonstrated commercial traction or an operating funding base. The company must continue investing in research and clinical development without product-sale inflows, leaving future financial progress dependent on trial outcomes and external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of reported debt reduces refinancing and interest-rate risk while preserving financial flexibility relative to a leveraged clinical-stage peer. Although the company remains loss-making, avoiding debt service gives management more discretion over capital allocation as clinical development continues.
Read all positive factors
Annovis Bio (ANVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$49.93M
Dividend YieldN/A
Average Volume (3M)1.12M
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue GrowthN/A
EPS Growth11.96%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.79
Shares Outstanding42,679,058
10 Day Avg. Volume946,249
30 Day Avg. Volume1,118,165
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.78
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.67Price Target Upside499.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.49
Revenue Forecast (FY)N/A
Annovis Bio Business Overview & Revenue Model
Company Description
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials ...
How the Company Makes Money
As a clinical-stage biotechnology company, Annovis Bio does not have commercialized products and, therefore, does not generate recurring revenue from product sales. Publicly available information indicates its funding historically comes primarily ...
Annovis Bio Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
24
Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -49.08M | -28.85M | -22.74M | -56.20M | -25.33M | -14.50M |
| Net Income | -49.52M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
Balance Sheet | ||||||
| Total Assets | 22.04M | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Cash, Cash Equivalents and Short-Term Investments | 18.73M | 19.53M | 10.55M | 5.75M | 28.38M | 45.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 26.29M | 4.23M | 4.62M | 17.96M | 7.70M | 1.51M |
| Stockholders Equity | -4.25M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
Cash Flow | ||||||
| Free Cash Flow | -43.34M | -25.62M | -21.89M | -39.97M | -17.31M | -9.13M |
| Operating Cash Flow | -43.34M | -25.62M | -21.89M | -39.97M | -17.31M | -9.13M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 44.94M | 34.60M | 26.69M | 17.34M | 4.61K | 46.74M |
Annovis Bio Technical Analysis
Negative
1.78
Price Trends
1.56
Negative
1.73
Negative
2.19
Negative
Market Momentum
-0.09
Negative
37.01
Neutral
39.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 1.78 is above the 20-day moving average (MA) of 1.23, above the 50-day MA of 1.56, and below the 200-day MA of 2.19, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 37.01 is Neutral, neither overbought nor oversold. The STOCH value of 39.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.
Annovis Bio Risk Analysis
Annovis Bio disclosed 77 risk factors in its most recent earnings report. Annovis Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Annovis Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $174.72M | -2.26 | -91.60% | ― | 3472.96% | 67.74% | |
50 Neutral | $149.70M | -1.24 | -136.27% | ― | ― | 27.94% | |
46 Neutral | $110.96M | -4.50 | -0.20% | ― | 1793.76% | 19.33% | |
44 Neutral | $214.35M | -3.30 | -53.89% | ― | -100.00% | -1813.57% | |
43 Neutral | $49.93M | -0.66 | -685.96% | ― | ― | 11.96% |
* Healthcare Sector Average
ANVS
Annovis Bio
1.18
-1.04
-46.85%
WHWK
Whitehawk Therapeutics
3.70
1.74
88.78%
DTIL
Precision BioSciences
6.31
0.87
15.99%
GLSI
Greenwich LifeSciences
16.98
6.07
55.64%
ABOS
Acumen Pharmaceuticals
2.04
0.31
17.92%
COYA
Coya Therapeutics, Inc.
4.81
-1.29
-21.15%
Annovis Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial
Positive
Jul 10, 2026
On July 7, 2026, Annovis Bio announced it had reached full enrollment in its pivotal Phase 3 trial testing buntanetap in patients with early Alzheimer’s disease. The study enrolled 850 patients with pTau217-confirmed Alzheimer’s pathol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.